OmniAb, Inc. (NASDAQ:OABI - Get Free Report) CFO Kurt Gustafson sold 9,301 shares of OmniAb stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $1.71, for a total transaction of $15,904.71. Following the completion of the sale, the chief financial officer directly owned 268,851 shares of the company's stock, valued at approximately $459,735.21. The trade was a 3.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
OmniAb Stock Performance
OABI opened at $1.71 on Thursday. The company's fifty day moving average price is $1.89 and its two-hundred day moving average price is $1.76. OmniAb, Inc. has a 1-year low of $1.22 and a 1-year high of $4.02. The company has a market cap of $246.17 million, a price-to-earnings ratio of -2.95 and a beta of 0.13.
Institutional Investors Weigh In On OmniAb
Institutional investors have recently added to or reduced their stakes in the company. Cadian Capital Management LP lifted its position in shares of OmniAb by 20.7% during the 4th quarter. Cadian Capital Management LP now owns 4,434,954 shares of the company's stock worth $8,205,000 after buying an additional 759,386 shares in the last quarter. Woodline Partners LP bought a new position in shares of OmniAb in the third quarter valued at approximately $4,571,000. Geode Capital Management LLC increased its position in shares of OmniAb by 17.0% during the fourth quarter. Geode Capital Management LLC now owns 2,722,692 shares of the company's stock valued at $5,038,000 after acquiring an additional 396,456 shares during the last quarter. Private Management Group Inc. lifted its holdings in OmniAb by 1.1% during the second quarter. Private Management Group Inc. now owns 2,558,045 shares of the company's stock worth $4,451,000 after acquiring an additional 28,286 shares during the period. Finally, Kent Lake PR LLC boosted its position in OmniAb by 677.8% in the second quarter. Kent Lake PR LLC now owns 1,750,000 shares of the company's stock worth $3,045,000 after purchasing an additional 1,525,000 shares during the last quarter. 72.08% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of OmniAb in a research report on Monday, December 22nd. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $6.67.
View Our Latest Stock Report on OmniAb
About OmniAb
(
Get Free Report)
OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.
Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
